Shu Wei Ren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shu Wei Ren has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Di Zhu
Department of Breast Surgery, Zhujiang Hospital, Southern Medical University, Guangdong, China
2 shared publications- Hai Yun Jin
Affiliation Department of Gynaecology and Obstetrics, Southern Hospital Taihe Branch, Southern Medical University, Guangdong, China
2 shared publications Jie Yu
Department of General Surgery, Zhujiang Hospital, Southern Medical University, Guangdong, China
2 shared publicationsShengming Lai
Department of Clinical Laboratory, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
2 shared publicationsYan Ouyang
Department of Clinical Laboratory, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
2 shared publications- Yongsheng Huang
Affiliation Cellular & Molecular Diagnostics Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong, China
2 shared publications
Latest Publications
- Open Access
- 6 November 2024
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 20 (11) , e1012284
A computational analysis of the oncogenic and anti-tumor immunity role of P4HA3 in human cancers
Prolyl-4-hydroxylase subunit alpha3 (P4HA3) is a triple helical procollagen synthesis protein. The role of P4HA3 in cancer development is not well known and lacks comprehensive analyses among human cancers. This study aimed to investigate the relationship between P4HA3 expression and anti-tumor immunity and its prognostic value in pan-cancer. P4HA3 expression was analyzed from TIMER2.0, GTEx, GEPIA2.0 and TCGA databases. Genetic and DNA methylation alterations, survival analysis and proteins co-expression analysis of P4HA3 in cBio Cancer Genomics Portal, TCGA, GSCA and TIMER2.0. The correlation between P4HA3 expression and immune infiltration was analyzed by TIDE, XCELL, MCPCOUNTER, and EPIC. We performed EdU and transwell experiments to evaluate the influence of P4HA3 on the proliferation, migration and invasion abilities of different tumors. Patients derived xenograft (PDX) and subcutaneous transplantation models were utilized to explore the correlation between P4HA3 and immunotherapy response in triple-negative breast cancer (TNBC). Among 33 types of cancers, P4HA3 had generally different expression between different tumors, further analysis showed that the expression of P4HA3 was correlated with the cells infiltration of the tumor microenvironment (TME). The expression of P4HA3 was positively with the cell proliferation markers and epithelial-mesenchymal transition (EMT) markers. Moreover, P4HA3 deficiency inhibited the proliferation, migration and invasion abilities of tumor cells, and promoted anti-tumor immunotherapy of PD-1/PD-L1 inhibitor. This pan-cancer analysis of P4HA3 provides a comprehensive understanding of its oncogenic and prognosis role in different cancers, P4HA3 abnormal expression could be a useful biomarker for predicting the effectiveness of immunotherapy in cancer patients.
- 6 November 2024
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 20 (11) , e1012284
Open AccessA computational analysis of the oncogenic and anti-tumor immunity role of P4HA3 in human cancers
Prolyl-4-hydroxylase subunit alpha3 (P4HA3) is a triple helical procollagen synthesis protein. The role of P4HA3 in cancer development is not well known and lacks comprehensive analyses among human cancers. This study aimed to investigate the relationship between P4HA3 expression and anti-tumor immunity and its prognostic value in pan-cancer. P4HA3 expression was analyzed from TIMER2.0, GTEx, GEPIA2.0 and TCGA databases. Genetic and DNA methylation alterations, survival analysis and proteins co-expression analysis of P4HA3 in cBio Cancer Genomics Portal, TCGA, GSCA and TIMER2.0. The correlation between P4HA3 expression and immune infiltration was analyzed by TIDE, XCELL, MCPCOUNTER, and EPIC. We performed EdU and transwell experiments to evaluate the influence of P4HA3 on the proliferation, migration and invasion abilities of different tumors. Patients derived xenograft (PDX) and subcutaneous transplantation models were utilized to explore the correlation between P4HA3 and immunotherapy response in triple-negative breast cancer (TNBC). Among 33 types of cancers, P4HA3 had generally different expression between different tumors, further analysis showed that the expression of P4HA3 was correlated with the cells infiltration of the tumor microenvironment (TME). The expression of P4HA3 was positively with the cell proliferation markers and epithelial-mesenchymal transition (EMT) markers. Moreover, P4HA3 deficiency inhibited the proliferation, migration and invasion abilities of tumor cells, and promoted anti-tumor immunotherapy of PD-1/PD-L1 inhibitor. This pan-cancer analysis of P4HA3 provides a comprehensive understanding of its oncogenic and prognosis role in different cancers, P4HA3 abnormal expression could be a useful biomarker for predicting the effectiveness of immunotherapy in cancer patients.
- Open Access
- 1 November 2024
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 13 (11) , 5830-5844
Pan-cancer analysis combined with experimental validation revealed that KTN1 is an immunological and prognostic biomarker
Background: Kinectin 1 (KTN1) is a membrane protein involved in intracellular organelle motility. However, the role of KTN1 in human pan-cancer lacks systematic analysis and evaluation. The aim of this study is to evaluate the expression profile and clinical value in human cancers by performing a pan-cancer analysis of KTN1. Methods: The expression of KTN1 and its correlation with cancer-associated fibroblasts (CAFs) infiltration were analyzed in TIMER2.0. The survival analysis, pathological stage correlation, and co-expression gene correlation analysis of KTN1 were performed on GEPIA2.0. We investigated the protein expression level of KTN1 in tumors through UALCAN. The cBioportal platform was used to analyze the variation frequency and type of KTN1. We used STRING database for protein-protein interaction (PPI) network analysis. Cell Counting Kit-8 (CCK8) and colony formation and transwell assay were performed to investigate the proliferation and migration abilities of head and neck squamous cell carcinoma (HNSC) cells with KTN1 knockdown. Results: KTN1 was differentially expressed in 12 kinds of cancer tissues compared with correspondent normal tissues. Meanwhile, the high expression of KTN1 was negatively correlated with the prognosis of HNSC, adrenocortical carcinoma (ACC), and liver hepatocellular carcinoma (LIHC). Further analysis suggested that patients with KTN1 mutations had better overall survival (OS) and progression-free survival than those without mutations among several cancers. Moreover, the level of CAFs and KTN1 expression were significantly correlated in 12 types of cancer. Mechanically, co-expression analysis showed the positive association between KTN1 and KTN1 antisense RNA 1 (KTN1-AS1), MNAT1 component of CDK activating kinase (MNAT1), N-alpha-acetyltransferase 30 (NAA30), protein phosphatase 2 regulatory subunit B’epsilon (PPP2R5E), and proteasome 26S subunit (PSMC6), which are mainly involved in the protein kinase AMP-activated catalytic subunit alpha 1 (AMPK) signaling pathway that regulates the progression of tumors. Conclusions: The functional experiment revealed that KTN1 promotes the proliferation and metastasis of HNSC cells. The pan-cancer analysis of KTN1 revealed its significance in different cancers, which provides a new marker for the diagnosis and prognosis of cancers.
- 1 November 2024
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 13 (11) , 5830-5844
Open AccessPan-cancer analysis combined with experimental validation revealed that KTN1 is an immunological and prognostic biomarker
Background: Kinectin 1 (KTN1) is a membrane protein involved in intracellular organelle motility. However, the role of KTN1 in human pan-cancer lacks systematic analysis and evaluation. The aim of this study is to evaluate the expression profile and clinical value in human cancers by performing a pan-cancer analysis of KTN1. Methods: The expression of KTN1 and its correlation with cancer-associated fibroblasts (CAFs) infiltration were analyzed in TIMER2.0. The survival analysis, pathological stage correlation, and co-expression gene correlation analysis of KTN1 were performed on GEPIA2.0. We investigated the protein expression level of KTN1 in tumors through UALCAN. The cBioportal platform was used to analyze the variation frequency and type of KTN1. We used STRING database for protein-protein interaction (PPI) network analysis. Cell Counting Kit-8 (CCK8) and colony formation and transwell assay were performed to investigate the proliferation and migration abilities of head and neck squamous cell carcinoma (HNSC) cells with KTN1 knockdown. Results: KTN1 was differentially expressed in 12 kinds of cancer tissues compared with correspondent normal tissues. Meanwhile, the high expression of KTN1 was negatively correlated with the prognosis of HNSC, adrenocortical carcinoma (ACC), and liver hepatocellular carcinoma (LIHC). Further analysis suggested that patients with KTN1 mutations had better overall survival (OS) and progression-free survival than those without mutations among several cancers. Moreover, the level of CAFs and KTN1 expression were significantly correlated in 12 types of cancer. Mechanically, co-expression analysis showed the positive association between KTN1 and KTN1 antisense RNA 1 (KTN1-AS1), MNAT1 component of CDK activating kinase (MNAT1), N-alpha-acetyltransferase 30 (NAA30), protein phosphatase 2 regulatory subunit B’epsilon (PPP2R5E), and proteasome 26S subunit (PSMC6), which are mainly involved in the protein kinase AMP-activated catalytic subunit alpha 1 (AMPK) signaling pathway that regulates the progression of tumors. Conclusions: The functional experiment revealed that KTN1 promotes the proliferation and metastasis of HNSC cells. The pan-cancer analysis of KTN1 revealed its significance in different cancers, which provides a new marker for the diagnosis and prognosis of cancers.
- Open Access
- 12 April 2024
- Published by Springer Nature in Research Square
A pan-cancer analysis of the oncogenic and anti-tumor immunity role of P4HA3 in human cancers
Background Prolyl-4-hydroxylase subunit alpha3 (P4HA3) is a triple helical procollagen synthesis protein. The role of P4HA3 in cancer development is not well known and lacks comprehensive analyses among human cancers. This study aimed to investigate the relationship between P4HA3 expression and anti-tumor immunity and its prognostic value in pan-cancer. Methods P4HA3 expression in pan-cancer patients were analyzed from TIMER2.0, Genotype Tissue Expression (GTEx), GEPIA2.0 and TCGA databases. Genetic and DNA methylation alterations, survival analysis and proteins co-expression analysis of P4HA3 in pan-cancer among numerous databases, including cBio Cancer Genomics Portal, TCGA, GSCA and TIMER2.0. The correlation between P4HA3 expression and immune infiltration was analyzed TIDE, XCELL, MCPCOUNTER, and EPIC. Gene function enrichment analysis was carried out by Gene Set Enrichment Analysis (GSEA). We performed EdU and transwell experiments to evaluate the influence of P4HA3 on the proliferation, migration and invasion abilities of 3 kinds of tumors in vitro. Patients derived xenograft (PDX) and subcutaneous transplantation models were utilized to explore the correlation between P4HA3 and immunotherapy response in triple-negative breast cancer (TNBC). Results Among 33 types of cancers, P4HA3 had generally different expression between tumor and tumor tissues, the abnormal expression of P4HA3 was associated with DNA methylation alteration and survival regimen of tumor patients. Further analysis showed that the expression of P4HA3 was correlated with the cells infiltration of the tumor microenvironment (TME), including immune cells, cancer-associated fibroblasts (CAFs), and stroma cells. Meanwhile, the expression of P4HA3 was positively with the cell proliferation markers and epithelial-mesenchymal transition (EMT) markers, that suggesting P4HA3 is involved in cancer proliferation and metastasis. Moreover, the molecular biology experiments in vitro and in vivo showed that P4HA3 deficiency inhibited the proliferation, migration and invasion abilities of tumor cells, and promoted anti-tumor immunotherapy of PD-1/PD-L1 inhibitor. Conclusion This pan-cancer analysis of P4HA3 provides a comprehensive understanding of its oncogenic and prognosis role in different cancers, P4HA3 abnormal expression could be a useful biomarker for predicting the effectiveness of immunotherapy in cancer patients.
- 12 April 2024
- Published by Springer Nature in Research Square
Open AccessA pan-cancer analysis of the oncogenic and anti-tumor immunity role of P4HA3 in human cancers
Background Prolyl-4-hydroxylase subunit alpha3 (P4HA3) is a triple helical procollagen synthesis protein. The role of P4HA3 in cancer development is not well known and lacks comprehensive analyses among human cancers. This study aimed to investigate the relationship between P4HA3 expression and anti-tumor immunity and its prognostic value in pan-cancer. Methods P4HA3 expression in pan-cancer patients were analyzed from TIMER2.0, Genotype Tissue Expression (GTEx), GEPIA2.0 and TCGA databases. Genetic and DNA methylation alterations, survival analysis and proteins co-expression analysis of P4HA3 in pan-cancer among numerous databases, including cBio Cancer Genomics Portal, TCGA, GSCA and TIMER2.0. The correlation between P4HA3 expression and immune infiltration was analyzed TIDE, XCELL, MCPCOUNTER, and EPIC. Gene function enrichment analysis was carried out by Gene Set Enrichment Analysis (GSEA). We performed EdU and transwell experiments to evaluate the influence of P4HA3 on the proliferation, migration and invasion abilities of 3 kinds of tumors in vitro. Patients derived xenograft (PDX) and subcutaneous transplantation models were utilized to explore the correlation between P4HA3 and immunotherapy response in triple-negative breast cancer (TNBC). Results Among 33 types of cancers, P4HA3 had generally different expression between tumor and tumor tissues, the abnormal expression of P4HA3 was associated with DNA methylation alteration and survival regimen of tumor patients. Further analysis showed that the expression of P4HA3 was correlated with the cells infiltration of the tumor microenvironment (TME), including immune cells, cancer-associated fibroblasts (CAFs), and stroma cells. Meanwhile, the expression of P4HA3 was positively with the cell proliferation markers and epithelial-mesenchymal transition (EMT) markers, that suggesting P4HA3 is involved in cancer proliferation and metastasis. Moreover, the molecular biology experiments in vitro and in vivo showed that P4HA3 deficiency inhibited the proliferation, migration and invasion abilities of tumor cells, and promoted anti-tumor immunotherapy of PD-1/PD-L1 inhibitor. Conclusion This pan-cancer analysis of P4HA3 provides a comprehensive understanding of its oncogenic and prognosis role in different cancers, P4HA3 abnormal expression could be a useful biomarker for predicting the effectiveness of immunotherapy in cancer patients.
- Open Access
- 22 February 2024
- Published by Global Journals in Global Journal of Medical Research
- Vol. 24 (F1) , 1-12
PPIB Unveiled: A Comprehensive Pan-Cancer Exploration Unraveling Immunological Signatures and Prognostic Implications
Background Peptidylprolyl isomerase B PPIB has been shown to play an essential role in tumor initiation and progression However it lacks systematic analysis and evaluation of the effect of PPIB on pan-cancer Methods The expression profile and survival analysis of PPIB in tumor tissues were demonstrated by the TIMER2 0 GEPIA2 0 and UALCAN online tools The cBioportal GSCA TISDB and TIMER2 0 databases were applied to analyze the correlation between PPIB and genetic variation immune infiltration and cancer-associated fibroblasts CAFs respectively The STRING GEPIA2 0 and TIMER2 0 databases were used to identify the co-expressed genes of PPIB The DAVID online database was used for GO and KEGG pathway analysis Results PPIB was highly expressed in 20 types of tumors Upregulation of PPIB was associated with a poor prognosis of 6 types of tumors P 0 05 In most cancers the frequency of PPIB genetic variation is relatively low and the common mutation types are missense mutations and splices
- 22 February 2024
- Published by Global Journals in Global Journal of Medical Research
- Vol. 24 (F1) , 1-12
Open AccessPPIB Unveiled: A Comprehensive Pan-Cancer Exploration Unraveling Immunological Signatures and Prognostic Implications
Background Peptidylprolyl isomerase B PPIB has been shown to play an essential role in tumor initiation and progression However it lacks systematic analysis and evaluation of the effect of PPIB on pan-cancer Methods The expression profile and survival analysis of PPIB in tumor tissues were demonstrated by the TIMER2 0 GEPIA2 0 and UALCAN online tools The cBioportal GSCA TISDB and TIMER2 0 databases were applied to analyze the correlation between PPIB and genetic variation immune infiltration and cancer-associated fibroblasts CAFs respectively The STRING GEPIA2 0 and TIMER2 0 databases were used to identify the co-expressed genes of PPIB The DAVID online database was used for GO and KEGG pathway analysis Results PPIB was highly expressed in 20 types of tumors Upregulation of PPIB was associated with a poor prognosis of 6 types of tumors P 0 05 In most cancers the frequency of PPIB genetic variation is relatively low and the common mutation types are missense mutations and splices